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government and private health insurers. Results: The total revenue and costs of 
PHI companies were 2.3 billion TL and 1.7 billion TL and per capita revenue and cost 
of private health insurance companies were 822 TL and 631 TL in 2013, respectively. 
The gross profit of all PHI companies was 0.6 billion or 26%. The SSI’s revenue and 
cost for health insurance were 53 billion and 49.9 billion TL, per capita revenue and 
cost of health insurance were 691 TL and 650 TL in 2013, respectively. The gross profit 
of SSI health insurance was 4.1 billion and 5%. ConClusions: The SSI has become 
the monopsonic payer in the Turkish health system with mandatory health insur-
ance premium collection from all Turkish citizen. The SSI determines its revenues 
and costs. Based on this power, the SSI has 4.1 billion gross revenue in total. This 
shows the success of SSI’s management while covering the whole population for a 
very comprehensive health care package. However, the SSI’s per capita revenue is 
lower and its cost is higher than private sector averages.
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objeCtives: To assess current status of HTA implementation in Central-Eastern 
European (CEE) countries and to identify long-term objectives considering country 
specific aspects and regional commonalities. Methods: An HTA implementation 
survey was designed to identify, present and discuss HTA roadmaps in CEE coun-
tries. The survey was conducted among participants at the Fifth Adriatic Congress 
of Pharmacoeconomics and Outcomes Research (Sibenik) and at the Pilot ISPOR HTA 
Training for CEE countries in June 2015 (Zagreb). Opinion of respondents on cur-
rent and preferred future status of HTA implementation in their own country were 
described related to capacity building, HTA financing, process and organisational 
structure for HTA, standardization of HTA methodology, use of local data, scope of 
mandatory HTA, and decision criteria. Results: 41 participants (78% public sector 
employees) from 11 CEE countries filled in the survey. 75% of respondents would 
prefer postgraduate training for HTA capacity building, however, only 15% reported 
a currently implemented program and 33% reported no regular HTA trainings in 
their countries. Participants would increase public funding on HTA research (6% 
current vs. 65% preferred) and on critical appraisal of HTA submissions (15% cur-
rent vs. 64% preferred). 73% of participants would prefer establishment of public 
HTA agency with academic support, however only 10% reported the existence of 
such agency. 92% of respondents would mandate the use of local data with need for 
assessing the transferability of international evidence (vs. 34% currently). 86% would 
prefer development of patient registries and access to data in payers’ databases (vs. 
11% currently). ConClusions: Our results must be viewed as an initial step in a 
multi-stakeholder dialogue on HTA implementation. Each CEE country should 
develop their own HTA roadmap, as such roadmaps are not fully transferable with-
out taking into account country size, GDP per capita, major social values, public 
health priorities and fragmentation of health care financing.
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objeCtives: The Italian Medicine Agency (AIFA) has recently introduced con-
ditional reimbursement schemes to promote access to oncology therapies, and 
reduce the risk of funding treatments with lower effectiveness than observed 
in clinical trials. These schemes are designed to be terminated after few years 
once treatment value is reassessed based on available real world data. Payment 
by Results (PbR) is frequently applied; manufacturers would be asked to pay back 
the treatment costs for patients receiving the new therapy if progression occurs 
before a pre-specified threshold. Methods: A simulation tool was built to assess 
the impact of the implementing PbR scheme and quantify the resulting increase 
in clinical value of a new treatment. Progression Free Survival (PFS) curves have 
been simulated using parametric distributions and hazard ratios to generate vari-
ous scenarios that may be observed in clinical trials. Patients receiving the new 
treatment and experiencing a recurrence before the PbR threshold were censored 
within the survival curves. PbR was also investigated considering Bevacizumab 
(Bev) in cervical cancer (CC). Results: The improvement in mPFS resulting of PbR 
was significant and meaningful in every scenario generated. The magnitude of the 
benefit depended mostly of the shape of parametric distribution. When applied 
to Bev in CC, a 3-month PbR scheme resulted in an improvement of Bev mPFS 
from 8.3 to 10.0 months (leading to a 4.1 months median incremental benefit over 
chemotherapy). ConClusions: Based on this simulation study, and the underlying 
assumptions, the patient access scheme proposed by AIFA would, in most scenarios, 
be associated with an increase in median incremental benefit for the patients, fewer 
costs for the payers and therefore better value for money.
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objeCtives: In recent years there has been an increasing strain on healthcare 
budgets. As a result, policymakers have adapted the framework for evaluating new 
medicines so manufacturers need to demonstrate additional benefit and value for 
money to achieve reimbursement. One of the key policy tools available are man-
aged entry agreements. In the UK these are assessed as patient access schemes 
(PAS) which have been successfully used to obtain cost effectiveness since 2007. 
information; collect pricing and reimbursement rules from each country; validate 
pricing and reimbursement rules monthly. The system was piloted by 3 affiliates 
(4 users). Results: The web-based system was introduced in March 2013, and 
has 246 users. The number of pricing applications/year increased from 124 (2012) 
with the Excel-based system to 455 (2013) and 312 (2014) with the web-based sys-
tem. The mean time for price approval/rejection decreased from approximately 
40 days (old system) to 6.5 days (new system). The mean time to respond to a 
pricing request decreased from 4 days (old system) to 0 days (i.e. information is 
available on new system). The estimated time needed to create monthly updates 
decreased from 1–2 days to 1–2 minutes (for simple reports). Further, the system 
enabled analyses to be performed internally, which would previously have been 
outsourced. ConClusions: The e-pricing system has improved the efficiency, 
reliability, compliance, transparency and ease of access to multinational drug 
pricing and approval information.
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objeCtives: Biosimilar discount expectations are often quoted at 20-30% of the 
originator’s price, but this benchmark was hugely underrated during recent tender 
bids in Norway. Orion Oyj astonished many when it decreased the price of its inf-
liximab biosimilar by 72%, a 69% discount vs. the originator. In our study, we aim 
to evaluate the risk of similar discounting levels occurring in the EU5 markets for 
IV biosimilars in the hospital setting. Methods: We evaluated IV biosimilar and 
originator biologic pricing, access and procurement policies across the EU5 markets 
to develop hypotheses on extreme biosimilar discounting risk levels. Results: All 
EU5 markets require biosimilars to launch at a discounted net price to attain reim-
bursement, and net pricing is negotiated at several levels. Regions and hospital pur-
chasing groups are anticipated to attain the greatest discounts or rebates, which will 
likely be greatest during exclusive or single-biosimilar source tenders that can shape 
biosimilar share. Payers using direct purchasing at the individual hospital level and 
those which leverage several non-price focused biosimilar adoption policies are 
expected to attain lower biosimilar discounts, due to reduced bargaining power or 
a lower dependence on cost savings to shape biosimilar uptake. ConClusions: We 
hypothesise that Spain, the UK and regions in Italy with exclusive tenders are at the 
greatest relative risk of repeating similar extreme discounting behaviours. France, 
Germany and regions in Italy not holding exclusive tenders are anticipated to realise 
lower biosimilar discounts. Furthermore, the lowest discounts are anticipated in 
non-hospital IV settings in Germany, where non-price focused biosimilar policies 
are expected to encourage adoption in treatment naïve patients, and exclusive 
rebate contracts with the originator will slow down switching of stable patients 
and biosimilar net price reductions.
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objeCtives: Activity-based financing (T2A) reforms in France in 2004 led to the 
creation of a list of high-cost drugs reimbursed outside the hospital budget, the 
“liste-en-sus”. In 2013, this spending was over 2.8 billion Euro, with 7.5% growth. 
Consequently, the French government has adopted multiple measures to control 
spending on “liste-en-sus” drugs. The most common measure taken is removal 
from the list. Patients and manufacturers have claimed that without such financ-
ing, removed drugs would not be prescribed, effectively denying access to certain 
products with marketing authorisation. We investigated the validity of this claim 
and the impact on healthcare spending of “liste-en-sus” removal. Methods: Using 
government ATIH data on “liste-en-sus” products and IMS MIDAS prescribing data, 
we identified 64 brands (48 molecules) removed from the list between 2007 and 2015. 
We then measured prescribing before and after removal and categorized the removal 
decisions. Results: Reasons for removal from the “liste-en-sus” can be categorised 
as follows: Price cut following launch of a generic or a biosimilar: 36 (20 molecules) 
Marketing authorization withdrawn: 3 Prescribing shift to retail setting: 4 Insufficient 
clinical value: 21 (of which 8 are announced for 2015/16). IMS MIDAS data analysis of 
the 13 products removed for insufficient clinical value between 2006-2013 shows that 
prescribing of half of these products was maintained or even increased, suggesting 
that removal did not deprive patients of authorized medicines. Sales of the remaining 
products fell after removal, as suitable alternatives were available for patients. For 
drug manufacturers, removal typically reduces sales; either through price discounts 
to achieve hospital reimbursement levels, or a fall in prescribing. ConClusions: 
The French “liste-en-sus” is meant to offer temporary funding for innovation, yet the 
number of removals is low. While removal has no negative consequences for patients, 
the real savings from such measures is limited and unlikely to reduce drug spending.
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objeCtives: The Health Transformation Program commenced in2002 by Ministry 
of Health(MoH) in Turkey. Today, Turkey has a well established health system 
mostly dominated by government as healthcare provider and payer. Social Security 
Institution(SSI) is the only government payer covering 99% of the Turkish population. 
There are private health insurance(PHI) companies covering only 3% of the popula-
tion. The aim of the analysis is to compared the profitability of health insurance 
in Turkey. Methods: The most updated data of revenue and cost of PHI data was 
obtained from Turkish Private Insurance Association for years 2009-2013. The official 
revenue and cost of government health insurance data was obtained from SSI for the 
same years. Descriptive analysis were conducted with the revenue and cost data of 
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objeCtives: As a consequence of Aging society, elderly people have growing need 
for long-term care and special nursing in their own homes as well. The focus of 
Hungarian health care system lacks the examination of health care provisions 
carried out in the social care system. This study aimed to assess the health care 
need within the residential social care institutions. Methods: In 2015 March-
May - with the support of State Secretary of Social Affairs of the Ministry of Human 
Capacities and the contribution of Hungarian Charity Service of the Order of Malta 
- in 12 residential social care institutions - caring about 600 elderly people - an 
empirical survey was carried out using datasheets focused on care problems and 
health care activities. Data were analysed by descriptive and regression statisti-
cal methods. Further qualitative analysis was carried out making interviews with 
directors of residential care homes. Results: Preliminary results showed that 
average age of inhabitants became increasingly higher (78 years). Growing rate of 
dementia (21.2%), need for intensive care (at least 12-hours a day), or continuous 
monitoring and special nursing (up to 35%) were observed. Our research has been 
continued with detailed analysis of use of special nursing care for the residents 
of social care institutions based on claim and utilization data of the National 
Health Insurance Fund Administration. ConClusions: More and more attention 
should be paid to nursing and other health care activities carried out in social 
care institutions. There is an urgent need for establishment of regulatory back-
ground, specification of human resources, competency level, and creation of incen-
tive system or separate financing. According to our preliminary budget impact 
analysis the normative cover of one site with advanced nursing care costs 500 
THUF, thus yearly 2 billion HUF could cover the operation of 4000 special nursing 
sites.
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objeCtives: To overview research methodologies related to external price ref-
erencing (EPR) in order to support an ongoing survey on 1) the comparison of 
European price corridor of pharmaceuticals and non-pharmaceutical services 
and 2) limitations in patient access to drugs in Central Eastern European (CEE) 
countries. Methods: Comprehensive review of peer reviewed and grey literature 
was conducted in 2015 February. Publications in PubMed database were searched 
using four keyword sets: #1 External reference pricing, #2 Central Eastern Europe, #3 
Consequences, #4 Pharmaceuticals. We used linkage as follows: #1 AND (#2 OR #3 OR 
#4). References from relevant publications and results from manual google search 
were also reviewed. Results: 422 publications were found and abstracts were 
screened by two independent researcher. 38 peer reviewed papers were included 
in the final evaluation. In addition 22 other documents (e.g. working papers by EU, 
WHO or OECD) were also included. EPR has high priority and widely used across 
Europe to price pharmaceuticals. There is an intense but unresolved scientific 
and public debate on choosing between differential pricing vs. narrow price cor-
ridor in Europe. There are several papers on the international price comparison 
of pharmaceuticals, however CEE countries are rarely involved in such studies. 15 
different methodological issues were identified with potentially strong influence 
on research conclusions, including differences in patent status, launch date, price 
category, price level, reimbursement status with or without restrictions in different 
indications, sales volume or confidential discounts. None of the reviewed studies 
took into account all identified issues. No studies with direct comparison of the 
pharmaceutical price corridor to the price corridor of non-pharmaceutical services 
were identified. ConClusions: Methodological issues may heavily influence the 
conclusions of research in international price comparison, and therefore potentially 
bias public opinion on to what extent EPR effects patient access in lower income 
European countries.
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objeCtives: Fractures due to falls are quite often reason for long hospitaliza-
tion and care dependency especially for the elderly. Thus, the reduction of cases 
and complications is of interest for medical insurance companies all over Europe. 
Therefore, the actual status including regional distribution has to be identified and 
drug prescription as one potential risk factor is analysed. Methods: Claims data 
(GAP-DRG) in the Austrian health care sector is used including many details for 
patient care. GAP-dRG (General Approach for Patient oriented Outpatient-based 
DRG) is a research data base with reimbursement data for outpatient services of 
sickness funds (social insurance) and Federal Ministry of Health (hospital data). 
Based on ICD10 diagnosis subgroups of fracture categories are analysed for the 
years 2001 to 2011. For the 32 health care regions data analysis divided into 5-years 
age group is performed. Data of persons with fracture and without is compared 
regarding their drug use, especially for anticoagulants, psychoanaleptics, urologi-
cals and calcium. RESULTS: In the years 2006 and 2007 over all 63.042 elderly (age 
60+) with a fracture main diagnosis were hospitalized in Austria. The incidences 
vary in the regions and in the 5-years age group. The youngest have an incidence 
rate of less than 10 per 1.000 persons, the old (age 90+) around 50 cases per 1.000 
persons and year. Looking at anticoagulants regional differences in prescription 
are identified, with an average of 80,7 percent, while the non-fracture population 
has only in 60,0 percent at least one prescription in 2006 or 2007 of an anticoagu-
lants. CONCLUSIONS: The realized work represents the actual Austrian situation. 
Additional analysis including longer wash-out phase and detailed analysis of 30-day 
mortality seem promising. Modeling and simulation of regional effects is under 
discussion.
PAS are negotiated on a case by case basis and range from simple discounts to 
more complex arrangements. The objective of this study was to assess the chang-
ing dynamics of PAS within the UK against a background of changing structures 
of healthcare delivery and a greater drive to save costs. Methods: A search of all 
approved Health Technology Assessments (HTAs) incorporating a PAS for either 
NICE or the SMC between October 2007 and June 2015 was undertaken. In addition, 
numerous sources including structured interviews were analysed to identify the 
key structure and changing dynamics of PAS. Results: 128 HTAs incorporating 
a PAS were approved by NICE or the SMC between October 2007 and June 2015. 
Out of these, 108 consisted of a simple discount on the list price. The remaining 
schemes were more complex in nature and included free stock, dose capping, sin-
gle fixed treatment price, response and rebate schemes. The majority of these PAS 
were incorporated into HTAs approved before August 2011, after which all PAS have 
consisted of a simple discount, with the exception of 3 cases, all of which were 
schemes transferred from earlier submissions for the same product in other indi-
cations. ConClusions: There has been a shift towards simple discount schemes 
in recent years as a preference from both the payer and manufacturer due to easy 
implementation and price confidentiality.
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objeCtives: In Germany, pharmaceutical manufacturers were free to set prices for 
prescription medicines approved for coverage under the statutory health insurance 
system. However, due to rapidly increasing prices for brand-name drugs and pre-
scribing behavior shifting towards expensive new drugs, Germany enacted legisla-
tion to fundamentally change the way of establishing the value of new drugs and 
using it as the basis for price negotiations. Since 2011, the Pharmaceutical Market 
Restructuring Act (Arzneimittelmarkt-Neuordnungsgesetz – AMNOG) has mandated 
that all newly introduced drugs be subject to an assessment of their benefits in rela-
tion to a comparator, typically the current standard treatment. Yet, market availabil-
ity is formally not affected by assessment results. Methods: Since January 2011, 
about 130 early benefit assessment procedures have been concluded. For about 100 
products, reimbursement amounts have also been determined. However, the impact 
of the results from the early benefit assessment on doctor’s prescription behavior is 
unknown. Based on prescription data from a large German sickness fund (6.3 million 
assured people) we examined to what extend the uptake of pharmaceutical innova-
tions increase in relation to the amount of additional benefit within twelve months 
after assessment results were published. Results: Our findings indicate that there 
is no correlation of the amount of additional benefit and likelihood of prescription. 
Products with a large benefit (“considerable”) feature a smaller uptake-rate (13%) 
than those with no approved benefit (19%). Medicines with a “minor” benefit show 
an uptake-rate of 18%, whereas those whose benefit is “not quantifiable” show 
the lowest with 7.5%. ConClusions: Multiple interacting factors influencing the 
uptake and diffusion of medicines besides additional benefit considerations. For 
instance, drug characteristics not considered within the benefit assessment that 
might lead to a patient-relevant benefit (such as the way of administration) and 
affect the likelihood of early adoption. Recent examples are given and discussed.
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objeCtives: The pharmacies and wholesalers remuneration system in Portugal, 
with drugs dispensing, suffered structural changes after the approval of the 
Memorandum of Understanding (MoU), signed in May 2011 by the Portuguese 
Government and International Authorities, which intensified the degree of public 
pharmaceutical expenditure reduction requirements, in exchange for the financial 
assistance. The objectives of present study were: to provide an overview of these 
changes, its impact for pharmacies (2011-2014) and recent advances towards a more 
comprehensive remuneration system. Methods: 1) literature review of the pub-
lished legislation and identification of changes; 2) market analysis and pharma-
cies and wholesalers margins were computed using Pharmacy Sales Information 
Systems (SICMED / hmR), two nationwide databases with representative drug dis-
pensing data from ambulatory care (and prescription data); 3) impact of changes and 
implications for the sector and pharmacies. The statistical analysis of the monthly 
data was performed using SAS, Guide 4.1. Results: The fixed linear remunera-
tion system was replaced in January 2012 by a regressive mark-up and minor fees 
system, per ex-factory price range (for pharmacies and wholesalers), determining 
the greatest change to the remuneration system during the last decades. In April 
2014, a fixed fee and a variable mark-up were added in the lowest and highest 
price range. The pharmaceutical market was reduced by 876 million euro and NHS 
expense by 494 million euro over the past four years. The loss of pharmacy and 
wholesaler remuneration was 322.8 Million euro in the same period (37% of the 
overall market reduction), higher to the established objective of 50 million euro in 
the MoU. ConClusions: Changes in the legislation, accentuated after MoU imple-
mentation, caused a large reduction in remuneration of pharmacies, due to directly 
cuts in margins and indirectly decrease in prices. Several studies, published in the 
meantime, support the difficulties for the sector sustainability.
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